Clinical Trial Update: Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide [Phase 4]

View source ↗

Summary

Phase 4 trial update on optimizing prevention of acute mountain sickness using remote ischemic preconditioning (RIPC) with acetazolamide.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mountain Sickness

Drugs mentioned

• ACETAZOLAMIDE (acetazolamide)
• RIPC (remote ischemic preconditioning)

Snippet

Sponsor: Ji Xunming,MD,PhD | Conditions: Acute Mountain Sickness | Phase 4 | Status: COMPLETED